Celgene (CELG)

Company Description

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.


86 Morris Avenue
Summit, NJ 07901
United States



Get BioInvest's perspective on Celgene's CEO

Latest Company News

Drilling Down Into Celgene Corporation (CELG) StockNewsJournal - 12 hours ago Celgene Corporation (CELG) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $127.58, down from yesterday's close by -2.80%. Traders Take Note: Celgene Corporation (NASDAQ:CELG) Stock Drops, Weakness in ... - CML News Brokerages Expect Celgene Corporation (CELG) Will Post Quarterly Sales of $3 ... - AppsforPCdaily [...]
Fri, Aug 18, 2017 4:52:00 PM, Continue reading at the source
How do I love thee, Celgene? Let me count the ways. Motley Fool - Aug 15, 2017 In my case, Celgene Corporation (NASDAQ:CELG) stands out among all the stocks that I own. It's so high on my list, that I named it a few months ago as the one stock I'd buy if I couldn't buy any other. [...]
Tue, Aug 15, 2017 12:00:00 PM, Continue reading at the source
Celgene slips 3% on modified oncology deal with Sutro Seeking Alpha - Aug 10, 2017 The market's down day notwithstanding, Celgene (CELG -2.8%) retreats on light volume on the heels of its revised immuno-oncology collaboration with Sutro. [...]
Thu, Aug 10, 2017 5:37:00 PM, Continue reading at the source
A Celgene-Ius Investment Seeking Alpha - Aug 10, 2017 Celgene's key revenue driver is the continued success in Revlimid. Rather alarmingly, it contributed to over 62% of the company's total revenue with global sales hitting $7bn. EPS is considerably lower than peers; however, this may pick up in due ... [...]
Thu, Aug 10, 2017 9:56:00 AM, Continue reading at the source
Celgene Paves The Way For Rare AML Patients Seeking Alpha - Aug 7, 2017 Phase 1/2 study data was so good that the FDA granted accelerated approval of Idhifa after phase 1/2 data, then ultimately approved it. [...]
Mon, Aug 07, 2017 11:37:00 AM, Continue reading at the source
Celgene: Expect The Story To Continue Seeking Alpha - Jul 28, 2017 Revlimid, Celgene's biggest drug, has grossed $2.0 billion in revenues, for a whopping 20% increase year over year - this strong performance came despite rather harsh comparables due to a Russian tender in Q2 2016 (which is why International sales ... [...]
Fri, Jul 28, 2017 1:08:00 AM, Continue reading at the source
Celgene Corporation Reports 28% Gain In Q2 Bottom Line Nasdaq - Jul 27, 2017 (RTTNews.com) - Celgene Corporation ( CELG ) reported earnings for its second quarter that increased from last year. The company said its bottom line rose to $1.47 billion, or $1.82 per share. [...]
Thu, Jul 27, 2017 11:37:00 AM, Continue reading at the source
Celgene: Gearing Up For New Highs Seeking Alpha - Jul 25, 2017 Celgene has double digit earnings growth, and strong revenue growth - seeing EPS grow from $0.94 to nearly $2.60 over the past 6 years. [...]
Tue, Jul 25, 2017 8:37:00 PM, Continue reading at the source
Celgene Settles Whistle-Blower Fraud Suit for $280 Million Bloomberg - Jul 25, 2017 Celgene Corp. agreed to pay $280 million to resolve a whistle-blower's claims the drugmaker used illegal marketing tactics to turn its Thalomid and Revlimid cancer drugs into blockbuster sellers, the U.S. Celgene Corporation Announces Settlement of Civil Litigation - Business Wire (press release) [...]
Tue, Jul 25, 2017 7:09:00 PM, Continue reading at the source
The case for Gilead Sciences Motley Fool - Jul 22, 2017 Even though sales are growing in general for the company's other drugs, particularly some of its newer HIV therapies, the drag from the hep C drugs is hard to overcome. [...]
Sat, Jul 22, 2017 3:33:00 PM, Continue reading at the source